On a there might be a Bottom Saucer or Rounding Reversal Pattern
Novavax (NASDAQ:NVAX) is a clinical-stage biotechnology company focused on the discovery , development and commercialisation of vaccines and adjuvants. Through its recombinant nanoparticle vaccine technology, it produces vaccine candidates to respond to both known and newly emerging diseases.
Novavax topped Wall Street expectations for the first quarter when it reported a loss of 58 cents per share on revenue of $3.4 million earlier this month. Analysts were expecting a loss of 69 cents per share and revenue of $1.9 million.
More importantly, the biotech company announced in its release that the Oslo-based nonprofit Coalition for Epidemic Preparedness Innovations will invest $384 million to advance the clinical development of its SARS-CoV-2 vaccine candidate, NVX-CoV2373.
Novavax plans to start human trials in May with preliminary results expected in July.